ArticleFrontiers in oncology2019
An Efficacious Endometrial Sampler for Screening Endometrial Cancer.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Diagnostic performance of CDO1 and ZSCAN12 methylation in endometrial versus cervical samples for endometrial cancer and atypical hyperplasia: a comparative study.Annals of medicine · 2026Article
- Integrating epigenetic and metabolic indicators for non-invasive endometrial cancer triage: a machine learning approach.BMC women's health · 2026Article
- Micro-histology combined with cytology improves the diagnostic accuracy of endometrial lesions.Cancer medicine · 2023Article
- Endometrial Cytology in Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis of Diagnostic Accuracy.Journal of clinical medicine · 2023Review
- Article
- Circular RNA hsa_circ_0011324 is involved in endometrial cancer progression and the evolution of its mechanism.Bioengineered · 2022Article
- HypermethylatedFrontiers in oncology · 2022Article
- Near-Infrared Fluorescent Agent forFrontiers in oncology · 2021Article
- Clinical Evaluation of Li Brush Endometrial Samplers for Diagnosing Endometrial Lesions in Women With Intrauterine Devices.Frontiers in medicine · 2020Article
- A Clinical Comparative Study of Two Different Endometrial Cell Samplers for Evaluation of Endometrial Lesions by Cytopathological Diagnosis.Cancer management and research · 2020Article
- Validation of Molecular Typing for Endometrial Screening Test That Predicts Benign and Malignant Lesions.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the research on early detection of precancerous change and endometrial carcinoma has been focusing on minimally invasive procedures for screening. On this basis, we aim to verify the feasibility of endometrial samplers for screening endometrial cancer using Li Brush. We recruited patients undergoing hysterectomy for different diseases from the Inpatient Department of the Department of Obstetrics and Gynecology. Before surgery, endometrial cells were collected by Li Brush. The cytopathologic diagnosis from Li Brush and the histopathologic diagnosis from hysterectomy in the same patient were compared to calculate sensitivity (Se), specificity (Sp), false-negative rate (FNR), false-positive rate (FPR), positive predictive value (PV+) %, and negative predictive value (PV-). The research enrolled 293 women into this self-controlled trial. According to the hypothesis test of paired four lattices, we obtained the following indicators: Se 92.73, Sp 98.15, FNR 7.27, FPR 1.85, PV+92.73, and PV-98.15%. The endometrial sampler Li Brush is an efficacious instrument for screening endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.